The British pharmaceutical giant AstraZeneca Plc will argue before Delaware’s Court of Chancery this week that claims it pushed biotech company Viela Bio Inc. into a sale with another drug company to avoid potential antitrust concerns are “fanciful allegations.”
Myasthenia Gravis Treatment Market Size, Share & Growth globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Second-Quarter 2023 Results: Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines GAAP Net Income of $127.1 Million; Adjusted EBITDA of.
First-Quarter 2023 Results: Net Sales of $832.1 Million GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million TEPEZZA® Net Sales of $405.3 Million . | May 3, 2023
The global antibody-mediated rejection prevention market is predicted to reach a valuation of US$ 89 million in 2023, with a compound annual growth rate (CAGR) of 16%, as per a recently published FMI report. Over the last decade, the complement system has emerged as an important constituent of the AMR market.Technol.
SAN DIEGO (BUSINESS WIRE) Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointments of Edward Hu and Kate Hermans to its Board of Directors.“I am deli.